SCHEMBL21458182

SCHEMBL21458182

O=C(NC1CC2(C1)CC(C(=O)O)C2)c1ccc(F)c2ccn(Cc3ccc(OC4CCCCC4)cc3)c12

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 14/20 0.40
▸ CNR1 P21554 13/20 0.40
▸ PTGER4 P35408 1/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ CCR3 P51677 1/20 0.38
▸ S1PR3 Q99500 1/20 0.37
▸ FAAH O00519 2/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31203084 0.99 PTGER4 (0.39) CNR2CNR1PTGER4CYP2D6CCR3
SCHEMBL21458130 0.99 PTGER4 (0.39) CNR2CNR1PTGER4CYP2D6CCR3
SCHEMBL21458146 0.92 S1PR3 (0.40) CNR2CNR1PTGER4S1PR3HRH3
SCHEMBL21458279 0.91 CNR1 (0.39) CNR2CNR1CYP2D6CCR3S1PR3
SCHEMBL21485549 0.91 CNR1 (0.41) CNR2CNR1CYP2D6CCR3S1PR3
SCHEMBL31203184 0.91 CNR2 (0.42) CNR2CNR1CYP2D6CCR3S1PR3
SCHEMBL21485548 0.91 CNR2 (0.44) CNR2CNR1FAAHHRH3
SCHEMBL22927176 0.90 CNR2 (0.45) CNR2CNR1FAAHHRH3
SCHEMBL24992157 0.90 CNR1 (0.40) CNR2CNR1CYP2D6CCR3S1PR3
SCHEMBL21506753 0.90 CNR2 (0.42) CNR2CNR1S1PR3FAAHHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 — — EP claimed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US claimed
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 — — US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 — — EP disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 — — US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 — — US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 — — US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 — — US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885PTGER4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback